Gilead Sciences, Inc. Live Share Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.849097375
Author: Trendlyne DVM scores

Strong Performer

about

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is...

109.64 -4.90 (-4.28%)

56.16% Gain from 52W Low

6.1M

XNAS Volume

XNAS 11 Jul, 2025 5:30 PM (EDT)

High Financial Strength

55.6 / 100

Affordable Valuation

50.7 / 100

Technically Moderately Bullish

66.2 / 100

Strong Performer These stock companies have strong financials and are affordably priced. They also score high in quality and technical aspects which makes them a favourite amongst investors. View Similar Embed DVM

117

1Yr Price target upside is 7%

26 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences, Inc. Live Share Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is...

56.16% Gain from 52W Low

SWOT Analysis

Gilead Sciences Live Price Chart